Haemonetics Corp

HAE NYSE Healthcare & Biotech United States US4050241003
78.20 $
2.05 %

Haemonetics Corp specializes in blood management products and services, including blood collection devices and operating room management systems.

Performance & Momentum

6 Months 8.80 %
1 Year 10.19 %
3 Years 9.21 %
5 Years 32.33 %

Strategic Analysis

Haemonetics Corp operates in a specialized niche within medical technology focused on the collection, separation, and management of blood and plasma. Its positioning is built on critical, recurring solutions for donors, collection centers, and plasma industry participants, giving it defensive exposure to a structural medical need.

Strengths
  • Niche expertise across an essential value chain in plasma and blood collection
  • Business supported by recurring uses and regulated needs, which enhances visibility
  • Technological positioning in medical devices, with an operational barrier to entry
Weaknesses
  • Dependence on a specialized market, which limits diversification of growth drivers
  • Recent stock market history has been more volatile than the long-term trend, suggesting higher market expectations
Momentum

Momentum appears moderately positive, but still fragile given the recent pullback in share price performance. The underlying trend remains mixed: the market seems to recognize the quality of the niche and the defensive profile, while remaining focused on the company’s ability to sustainably reaccelerate after a period of underperformance.

Similar stocks to Haemonetics Corp

Anantys Community

Be the first to share your analysis on Haemonetics Corp.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases